1. Tzouvelekis A, Spagnolo P, Bonella F, et al. Patients with IPF and lung cancer: diagnosis and management. Lancet Respir Med. 2018;6(2):86-88. doi:10.1016/S2213-2600(17)30478-2
2. Yoo H, Jeong BH, Chung, MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2019;19(1):149. doi:10.1186/s12890-019-0905-8
3. Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer. Curr Opin Pulm Med. 2015;21(6):626-633. doi:10. 1097/MCP.0000000000000217
4. Masai K, Tsuta K, Motoi N, et al. Clinicopathological, immunohistochemical, and genetic features of primary lung adenocarcinoma occurring in the setting of usual interstitial pneumonia pattern. J Thorac Oncol. 2016;11(12): 2141-2149. doi:10.1016/j.jtho.2016.07.034
5. Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep. 2021;11(1):8312. doi:10. 1038/s41598-021-87747-1
6. Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D. Common pathogenic mechanisms between idiopathic pulmonary fibrosis and lung cancer. Chest. 2019;156(2):383-391. doi:10.1016/j.chest.2019.04. 114
7. Wolters PJ, Blackwell TS, Eickelberg O, et al. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018;6(2):154-160. doi:10.1016/S2213-2600(18)30007-9
8. Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep. 2021;11(1):8312. doi:10. 1038/s41598-021-87747-1
9. Demopoulos K, Arvanitis DA, Vassilakis DA, Siafakas NM, Spandidos DA. MYCL1, FHIT, SPARC, p16 INK4 and TP53 genes associated to lung cancer in idiopathic pulmonary fibrosis. J Cell Mol Med. 2002;6(2):215-222. doi:10.1111/j.1582-4934.2002.tb00188.x
10. Liu T, Chung MJ, Ullenbruch M, et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Investig. 2007; 117(12):3800-3809. doi:10.1172/JCI32369
11. Drakopanagiotakis F, Krauss E, Michailidou I, et al. Lung cancer and ınterstitial lung diseases.Cancers (Basel). 2024;16(16):2837. doi:10.3390/cancers16162837
12. Wang C, Yang J. Mechanical forces: the missing link between idiopathic pulmonary fibrosis and lung cancer. Eur J Cell Biol. 2022;101(3):151234. doi:10.1016/j.ejcb.2022.151234
13. Malli F, Koutsokera A, Paraskeva E, et al. Endothelial progenitor cells in the pathogenesis of idiopathic pulmonary fibrosis: an evolving concept. PLoS ONE. 2013;8(1):e53658. doi:10.1371/journal.pone.0053658
14. Archontogeorgis K, Steiropoulos P, Tzouvelekis A, Nena E, Bouros D. Lung cancer and interstitial lung diseases: a systematic review. Pulm Med. 2012; 2012:315918. doi:10.1155/2012/315918
15. Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis. Proc Am Thorac Soc. 2012;9(3):111-116. doi:10.1513/pats.201203-023AW
16. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543-550. doi:10. 1038/nature13385
17. Kidera Y, van Tsubaki M, Yamazoe Y, et al. Reduction of lung metastasis, cell invasion, and adhesion in mouse melanoma by statin-induced blockade of the Rho/Rhoassociated coiled-coil-containing protein kinase pathway. J Exp Clin Cancer Res. 2010;29(1):127. doi:10.1186/1756-9966-29-127
18. Lovat F, Valeri N, Croce CM. MicroRNAs in the pathogenesis of cancer. Semin Oncol. 2011;38(6):724-733. doi:10.1053/j.seminoncol.2011.08.006
19. Sgalla G, Larici AR, Golfi N, et al. Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. BMC Pulm Med. 2020;20(1):249. doi:10.1186/s12890-020-01289-2
20. Lee J, Kim C, Seol HY, et al. Safety and diagnostic yield of radial probe endobronchial ultrasound-guided biopsy for peripheral lung lesions in patients with idiopathic pulmonary fibrosis: a multicenter cross-sectional study. Respiration. 2022;101(4):401-407. doi:10.1159/000520034
21. Bargagli E, Bonti V, Ferrari K, et al. Lung cancer in patients with severe idiopathic pulmonary fibrosis: critical aspects. In Vivo. 2017;31(4):773-777. doi:10.21873/invivo.11130
22. Axtell AL, David EA, Block MI, Parsons N, Habib R, Muniappan A. Association between interstitial lung disease and outcomes after lung cancer resection. Ann Thorac Surg. 2023;116(3):533-541. doi:10.1016/j.athoracsur.2023.04.042
23. Saito Y, Kawai Y, Takahashi N, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92(5):1812-1817. doi:10.1016/j.athoracsur. 2011.06.055
24. Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125(6):1321-1327. doi:10.1016/s0022-5223(03)00028-x
25. Goto T. Measuring surgery outcomes of lung cancer patients with concomitant pulmonary fibrosis: a review of the literature. Cancers. 2018; 10(7):223. doi:10.3390/cancers10070223
26. Sato T, Teramukai S, Kondo H, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg. 2014;147(5):1604-1611. doi:10.1016/j.jtcvs.2013.09.050
27. Qubo AA, Numan J, Snijder J, et al. Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe (Sheff). 2022;18(4):220147. doi:10.1183/20734735.0147-2022
28. Sakairi Y, Yoshino I, Iwata T, et al. A randomized controlled phase III trial protocol: perioperative pirfenidone therapy in patients with non-small cell lung cancer combined with idiopathic pulmonary fibrosis to confirm the preventative effect against postoperative acute exacerbation: the PIII-PEOPLE study (NEJ034). J Thorac Dis. 2023;15(3):1486-1493. doi:10. 21037/jtd-22-535
29. Li F, Liu H, Wu H, Liang S, Xu Y. Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy. Radiat Oncol. 2021;16(1):70. doi:10.1186/s13014-021-01798-2
30. Kim H, Pyo H, Noh JM, et al. Preliminary result of definitive radiotherapy in patients with non-small cell lung cancer who have underlying idiopathic pulmonary fibrosis: comparison between X-ray and proton therapy. Radiat Oncol. 2019;14(11):19. doi:10.1186/s13014-019-1221-4
31. Karampitsakos T, Spagnolo P, Mogulkoc N, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: a retrospective multicentre study in Europe. Respirology. 2023;28(1):56-65. doi:10.1111/resp.14363
32. Tzouvelekis A, Antoniou K, Kreuter M, et al. The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Res. 2021;7(1):00529-2020. doi:10.1183/23120541.00529-2020
33. Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO clinical practice guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12): 1637-1642. doi:10.1016/j.annonc.2021.08.1994
34. Wang Z, Bai J, Liu Y, Li P, Jiao G. Risk factors for acute exacerbation of interstitial lung disease during chemotherapy for lung cancer: a systematic review and meta-analysis. Front Oncol. 2023;13:1250688. doi:10.3389/fonc. 2023.1250688
35. Kenmotsu H, Naito T, Kimura Mi, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6(7):1242-1246. doi:10.1097/JTO.0b013e318216ee6b
36. Watanabe N, Taniguchi H, Kondoh Y, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85(4):326-331. doi:10.1159/000342046
37. Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011; 71(1):70-74. doi:10.1016/j.lungcan.2010.04.014
38. Wang Y, Miao L, Hu Y, Zhou Y. The efficacy and safety of first-line chemotherapy in patients with non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis. Front Oncol. 2020;10: 1636. doi:10.3389/fonc.2020.01636
39. Fujita T, Kuroki T, Hayama N, et al. Pemetrexed plus platinum for patients with advanced non-small cell lung cancer and interstitial lung disease. In Vivo. 2019;33(6):2059-2064. doi:10.21873/invivo.11704
40. Suh CH, Kim KW, Pyo J, Hatabu H, Nishino M. The incidence of ALK inhibitor-related pneumonitis in advanced non-small-cell lung cancer patients: a systematic review and meta-analysis. Lung Cancer. 2019;132:79-86. doi:10.1016/j.lungcan.2019.04.015
41. Fukuda Y, Uchida Y, Ando K, Manabe R, Tanaka A, Sagara H. Risk factors for interstitial lung disease in patients with nonsmall cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors: a systematic review and meta-analysis. Respir Investig. 2024;62(3):481-487. doi:10.1016/ j.resinv.2024.03.007
42. Zhou S, Kishi N, Alerasool P, Rohs NC. Adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: an updated meta-analysis. Target Oncol. 2024;19(4):547-564. doi: 10.1007/s11523-024-01073-w
43. Yamamoto Y, Yano Y, Kuge T, et al. Safety and effectiveness of pirfenidone combined with carboplatin-based chemotherapy in patients with idiopathic pulmonary fibrosis and non-small cell lung cancer: a retrospective cohort study. Thorac Cancer. 2020;11(11):3317-3325. doi:10.1111/1759-7714. 13675
44. Wang Y, Gong X, Hu Y, et al. Anti-angiogenic drugs inhibit interstitial lung disease progression in patients with advanced non-small cell lung cancer. Front Oncol. 2022;12:873709. doi:10.3389/fonc.2022.873709
45. Lee TH, Chen HL, Tsai MJ, Yang, CJ. EGFR-TKI plus antiangiogenic agent combination therapy may reduce the incidence of EGFR-TKI-associated interstitial lung disease in Asian. Kaohsiung J Med Sci. 2022;38(11):1133-1134. doi:10.1002/kjm2.12584
46. Tan J, Xue Q, HuX, Yang J. Inhibitor of PD-1/PD-L1: a new approach may be benefcial for the treatment of idiopathic pulmonary fbrosis. J Transl Med. 2024;22(1):95. doi:10.1186/s12967-024-04884-7
47. Shibaki R, Murakami S, Matsumoto Y, et al. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Med Oncol. 2019;36(6):49. doi:10.1007/s12032-019-1274-0
48. Zhang M, Fan Y, Nie L, Wang G, Sun K, Cheng Y. Clinical outcomes of immune checkpoint inhibitor therapy in patients with advanced non-small cell lung cancer and preexisting interstitial lung diseases: a systematic review and meta-analysis. Chest. 2022;161(6):1675-1686. doi:10.1016/j.chest.2021.12.656
49. Tasaka Y, Honda T, Nishiyama N, et al. Noninferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2021;155:120-126. doi:10.1016/j.lungcan.2021.03.014
50. Kanai O, Kim YH, Demura Y, et al. Efcacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847-855. doi:10.1111/1759-7714.12759
51. Qin W, Zou J, Huang Y, et al. Pirfenidone facilitates immune infltration and enhances the antitumor efcacy of PD-L1 blockade in mice. Oncoimmunology. 2020;9(1):1824631. doi:10.1080/2162402X.2020.1824631